The Potential Role of TGFβ1, TGFβ2 and TGFβ3 Protein Expression in Colorectal Carcinomas: Correlation with Classic Histopathologic Factors and Patient Survival

Strahlentherapie und Onkologie

Volumn 180, Issue 4, 2004, Pages 201-208

  Tsamandas, Athanassios C ^a   Kardamakis, Dimitrios ^a   Ravazoula, Panagiota ^a   Zolota, Vassiliki ^a   Salakou, Stavroula ^a   Tepetes, Konstantinos ^a   Kalogeropoulou, Cristina ^a   Tsota, Irene ^a   Kourelis, Theodore ^a   Makatsoris, Thomas ^a   Karavias, Dionissios ^a   Scopa, Chrisoula D ^a   Bonikos, Dionysis S ^a   Kalofonos, Haralambos P ^a   Petsas, Theodore ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Colorectal carcinoma; Prognostic factors; Transforming growth factor beta

Indexed keywords

ANTIBODY; BIOTIN; STREPTAVIDIN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; ANTINEOPLASTIC ANTIMETABOLITE; FLUOROURACIL; FOLINIC ACID; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COLON ADENOCARCINOMA; COLON MUCOSA; COLORECTAL CARCINOMA; EPITHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; PATHOGENESIS; PATHOLOGY; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; TUMOR CLASSIFICATION; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; COLON; COLORECTAL TUMOR; COMPARATIVE STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; EVALUATION; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; POSTOPERATIVE CARE; PROPORTIONAL HAZARDS MODEL; RADIATION DOSE; RECTUM; SURVIVAL; TIME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COLON; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; POSTOPERATIVE CARE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY DOSAGE; RECTUM; SURVIVAL ANALYSIS; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 11144357377     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-004-1149-x     Document Type: Article

References (35)

1. Akiyama Y, Iwanaga R, Ishikawa T, et al. Mutations of the transforming growth factor-beta type II receptor gene are strongly related to sporadic proximal colon carcinomas with microsatellite instability. Cancer 1996;78:2478-84.
2. Akiyama Y, Iwanaga R, Saitoh K, et al., Transforming growth factor beta type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer. Gastroenterology 1997;112:33-9.
3. Allal AS, Bischof S, Nouet P. Impact of the "belly-board" device on treatment reproducibility in preoperative radiotherapy for rectal cancer. Strahlenther Onkol 2002;178;259-62.
4. Avery A, Paraskeva C, Hall P, et al. TGF-beta expression in the human colon: differential immunostaining along crypt epithelium. Br J Cancer 1993;68:137-9.
5. Bellone G, Carbone A, Tibaudi D, et al. Differential expression of transforming growth factors-β1, -β2 and -β3 in human colon carcinoma. Eur J Cancer 2001;37:224-33.
6. Cardillo MR, Yap E. TGF-beta1 in colonic neoplasia: a genetic molecular and immunohistochemical study. J Exp CLin Cancer Res 1997;16:281-8.
7. Colon and rectum (ICD-0 C18-C20) in TNM classification of malignant tumors (UICC - International Union against Cancer). Sobin LH, Wittekind C, eds. New York: Wiley-Liss, 2002:72-6.
8. Friedman E, Gold LI, Klimstra D, et al. High Levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev 1995;4:549-54.
9. Grau AM, Zhang L, Wang W, et al. Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. Cancer Res 1997;57:3929-34.
10. Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 1994;371:257-61.
11. Hoffmann KT, Rau B, Wust P, et al. Restaging of locally advanced carcinoma of the rectum with MR imaging after preoperative radio-chemotherapy plus regional hyperthermia. Strahlenther Onkol 2002;178:386-92.
12. Howe JR, Roth S, Ringold JC, et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 1998;280:1086-8.
13. Jass JR, Sobin LH. Histological typing of intestinal tumors: World Health Organization, 2nd edn. New York: Springer, 1989.
14. Kucharzik T, Lugering N, Winde G, et al. Colon carcinoma cell lines stimulate monocytes and lamina propria mononuclear cells to produce IL-10. Clin Exp Immunol 1997;110:296-302.
15. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998;67:753-91.
16. Matsushita M, Matsuzaki K, Date M, et al. Down-regulation of TGF-beta receptors in human colorectal cancer: implications for cancer development. Br J Cancer 1999;80:194-205.
17. Miyaki M, Iijima T, Kimura J, et al. Frequent mutation of beta-catenin and APC genes in primary colorectal tumors from patients with hereditary nonpolyposis colorectal cancer. Cancer Res 1999;59:4506-9.
18. Parsons R, Myeroff L, Liu B, et al. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res 1995;55:5548-50.
19. Proetzel G, Pawlowski SA, Wiles MV, et al. Transforming growth factor-beta 3 is required for secondary palate fusion. Nat Genet 1995;11:409-14.
20. Reynisdottir I, Polyak K, Iavarone A, et al. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev 1995;9:1831-45.
21. Rödel F, Hoffmann J, Grabenbauer GG, et al. High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol 2002;178:426-35.
22. Rosai J. Ackerman's surgical pathology, vol 1, 8th edn. St. Louis: Mosby, 1996:729-99.
23. Sandhu C, Garbe J, Bhattacharya N, et al. Transforming growth factor beta stabilizes p151NK4B protein, increases p151NK4B-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells. Mol Cell Biol 1997;17:2458-67.
24. Sanford LP, Ormsby I, Gittenberger-de Groot AC, et al. TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development 1997;124:2659-70.
25. Sauer R, Fietkau R, Wittekind C, et al. Adjuvant versus neoadjuvant radiochemotherapy for locally advanced rectal cancer. A progress report of a phase-III randomized trial (protocol CAO/ARO/AIO-94). Strahlenther Onkol 2001;177:173-81.
26. Scopa CD, Vagianos C, Kardamakis D, et al. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with rectal cancer. Appl Immunohistochem Mol Morphol 2001;9:329-34.
27. Shim KS, Kim KH, Han WS, et al. Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection. Cancer 1999;85:554-61.
28. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992;359:693-9.
29. Tanaka S, Imanishi K, Yoshihara M, et al. Immunoreactive transforming growth factor alpha is commonly present in colorectal neoplasia. Am J Pathol 1991;139:123-9.
30. Tanaka S, Miyazaki H, Takeda Y, et al. Detection of serum cytokine levels in experimental cancer cachexia of colon 26 adenocarcinoma-bearing mice. Cancer Lett 1993;72:65-70.
31. Togo G, Toda N, Kanai F, et al. A transforming growth factor beta type II receptor gene mutation common in sporadic cecum cancer with microsatellite instability. Cancer Res 1996;56:5620-3.
32. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994;78:67-74.
33. Tsamandas AC, Zolota V, Batistatou A, et al. The potential role of TGFβ1, p21 and Ki67 expression in colorectal carcinomas. Hepatogastroenterology 2001;48:Suppl 1:CLI.
34. Tsushima H, Kawata S, Tamura S, et al. High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression. Gastroenterology 1996;110:375-82.
35. Yagi OK, Akiyama Y, Ohkura Y, et al. Analyses of the APC and TGF-beta type II receptor genes, and microsatellite instability in mucosal colorectal carcinomas. Jpn J Cancer Res 1997;88:718-24.